A secondary endpoint of the EMILIA study was time to symptom worsening ( time from randomization to the first documentation of a 5-point decrease from baseline ) as measured by the Trial Outcome Index Physical/Functional/Breast ( TOI-PFB ) subset of the Functional Assessment of Cancer Therapy-Breast questionnaire .